Mostrar el registro sencillo del ítem
dc.contributor.author | Álvarez, Beatriz | |
dc.contributor.author | Navarrete-Muñoz, María A | |
dc.contributor.author | Briz, Veronica | |
dc.contributor.author | Olmedillas-López, Susana | |
dc.contributor.author | Nistal, Sara | |
dc.contributor.author | Cabello, Alfonso | |
dc.contributor.author | Prieto, Laura | |
dc.contributor.author | Górgolas, Miguel | |
dc.contributor.author | García-Arranz, Mariano | |
dc.contributor.author | Benito, José Miguel | |
dc.contributor.author | Rallón, Norma | |
dc.date.accessioned | 2022-05-24T10:20:14Z | |
dc.date.available | 2022-05-24T10:20:14Z | |
dc.date.issued | 2022-03-24 | |
dc.identifier.citation | Sci Rep. 2022 Mar 24;12(1):5095. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/14483 | |
dc.description.abstract | The role of HCV on the HIV reservoir is controversial since the reduction on HIV-DNA levels after HCV eradication with IFNα/RBV treatment seems to be the result of drugs instead of HCV clearance. We assessed whether HCV eradication can decrease HIV-DNA content in HIV/HCV-coinfected patients treated with direct-acting antivirals, DAAs (IFNα/RBV-free regimens). Cell-associated HIV-DNA was measured by ddPCR in 25 HIV-monoinfected and 25 HIV/HCV-coinfected patients. There were no differences in HIV-DNA levels between groups neither at baseline nor at 12 weeks after DAAs treatment completion. Our results indicate that HCV does not appear to influence the HIV reservoir size and suggest the lack of an anti-HIV action for DAAs. | es_ES |
dc.description.sponsorship | This work was supported by projects PI14/00518, RD16/0025/0013 integrated into the State Plan for Scientific and Technical Research and Innovation from the General Sub-Directorate for research assessment and promotion, Spanish Carlos III Institute of Health (ISCIII) co-funded by the European Regional Development Fund (ERDF). Maria A Navarrete-Muñoz was funded by the Spanish Directorate General for Research and Technological of the “Comunidad de Madrid” [grant: IND2018/BMD9651]. Norma Rallón is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III [grant: CPII19/00025]. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Nature Publishing Group | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.title | HIV-reservoir size is not affected either by HCV coinfection or by direct acting antivirals (DAAs) therapy | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 35332180 | es_ES |
dc.format.volume | 12 | es_ES |
dc.format.number | 1 | es_ES |
dc.format.page | 5095 | es_ES |
dc.identifier.doi | 10.1038/s41598-022-08871-0 | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | Plan Nacional de I+D+i (España) | es_ES |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | es_ES |
dc.contributor.funder | Comunidad de Madrid (España) | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 2045-2322 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1038/s41598-022-08871-0 | es_ES |
dc.identifier.journal | Scientific Reports | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//RD16%2F0025%2F0013/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN SIDA (RIS)/ | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PI14/00518 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/CPII19/00025 | es_ES |